Drug Profile
AZD 8154
Alternative Names: AZD-8154Latest Information Update: 21 Nov 2023
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Antiasthmatics
- Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors; Phosphatidylinositol 3 kinase gamma inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 09 Sep 2023 Pharmacodynamics data from a preclinical study in Asthma presented at the 33rd Annual Congress of the European Respiratory Society (ERS-2023)
- 14 May 2021 Pharmacodynamics data from preclinical trial in Asthma presented at the 117th International Conference of the American Thoracic Society (ATS-2021)
- 01 Apr 2021 Discontinued - Phase-I for Asthma (In volunteers) in Germany (Inhalation, Powder) (AstraZeneca pipeline, May 2021)